BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 33382529)

  • 21. Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
    Makita S; Yamamoto G; Maruyama D; Asano-Mori Y; Kaji D; Ananthakrishnan R; Ogasawara K; Stepan L; Schusterbauer C; Rettby N; Hasskarl J; Izutsu K
    Cancer Med; 2022 Dec; 11(24):4889-4899. PubMed ID: 35619325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma.
    Iacoboni G; Villacampa G; Martinez-Cibrian N; Bailén R; Lopez Corral L; Sanchez JM; Guerreiro M; Caballero AC; Mussetti A; Sancho JM; Hernani R; Abrisqueta P; Solano C; Sureda A; Briones J; Martin Garcia-Sancho A; Kwon M; Reguera-Ortega JL; Barba P;
    Cancer Med; 2021 May; 10(10):3214-3223. PubMed ID: 33932100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.
    Gauthier J; Hirayama AV; Purushe J; Hay KA; Lymp J; Li DH; Yeung CCS; Sheih A; Pender BS; Hawkins RM; Vakil A; Phi TD; Steinmetz RN; Shadman M; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2020 May; 135(19):1650-1660. PubMed ID: 32076701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
    Wang Y; Jain P; Locke FL; Maurer MJ; Frank MJ; Munoz JL; Dahiya S; Beitinjaneh AM; Jacobs MT; Mcguirk JP; Vose JM; Goy A; Andreadis C; Hill BT; Dorritie KA; Oluwole OO; Deol A; Paludo J; Shah B; Wang T; Banerjee R; Miklos DB; Rapoport AP; Lekakis L; Ghobadi A; Neelapu SS; Lin Y; Wang ML; Jain MD
    J Clin Oncol; 2023 May; 41(14):2594-2606. PubMed ID: 36753699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.
    Yan L; Qu S; Shang J; Shi X; Kang L; Xu N; Zhu M; Zhou J; Jin S; Yao W; Yao Y; Chen G; Chang H; Zhu X; Yu L; Wu D; Fu C
    Cancer Med; 2021 Jan; 10(2):563-574. PubMed ID: 33356013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistent Cytopenia After CD19 CAR T Therapy in Relapsed/Refractory DLBCL Patients Could Be a Predictor of Efficacy and Side Effects.
    Li J; Mu J; Wang J; Li X; Li Q; Jiang Y; Cui R; Deng Q
    Cell Transplant; 2024; 33():9636897241247951. PubMed ID: 38651796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.
    Kuhnl A; Roddie C; Kirkwood AA; Tholouli E; Menne T; Patel A; Besley C; Chaganti S; Sanderson R; O'Reilly M; Norman J; Osborne W; Bloor A; Lugthart S; Malladi R; Patten PEM; Neill L; Martinez-Cibrian N; Kennedy H; Phillips EH; Jones C; Sharplin K; El-Sharkawi D; Latif AL; Mathew A; Uttenthal B; Stewart O; Marzolini MAV; Townsend W; Cwynarski K; Ardeshna K; Ardavan A; Robinson K; Pagliuca A; Collins GP; Johnson R; McMillan A
    Br J Haematol; 2022 Aug; 198(3):492-502. PubMed ID: 35485402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
    Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
    J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Case Report: CD19 CAR T-cell therapy following autologous stem cell transplantation: a successful treatment for R/R CD20-negative transformed follicular lymphoma with
    Zhang J; Cai D; Gao R; Miao Y; Cui Y; Liu Z; Zhang H; Yan X; Su N
    Front Immunol; 2023; 14():1307242. PubMed ID: 38143763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
    George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
    BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
    Kochenderfer JN; Somerville RPT; Lu T; Yang JC; Sherry RM; Feldman SA; McIntyre L; Bot A; Rossi J; Lam N; Rosenberg SA
    Mol Ther; 2017 Oct; 25(10):2245-2253. PubMed ID: 28803861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
    Neelapu SS; Chavez JC; Sehgal AR; Epperla N; Ulrickson M; Bachy E; Munshi PN; Casulo C; Maloney DG; de Vos S; Reshef R; Leslie LA; Oluwole OO; Yakoub-Agha I; Khanal R; Rosenblatt J; Korn R; Peng W; Lui C; Wulff J; Shen R; Poddar S; Jung AS; Miao H; Beygi S; Jacobson CA
    Blood; 2024 Feb; 143(6):496-506. PubMed ID: 37879047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.
    Kato K; Fujii N; Makita S; Goto H; Kanda J; Shimada K; Akashi K; Izutsu K; Teshima T; Fukuda N; Sumitani T; Nakamura S; Sumi H; Shimizu S; Kakurai Y; Yoshikawa K; Tobinai K; Usui N; Hatake K
    Int J Hematol; 2023 Mar; 117(3):409-420. PubMed ID: 36399286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
    Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
    Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CAR T-Cells for the Treatment of Refractory or Relapsed Large B-Cell Lymphoma: A Single-Center Retrospective Canadian Study.
    Benoit A; B Boies MH; Déry N; M Garcia L; Simard M; Poirier M; Delage R; Lortal Canguilhem B; Doyle C; Larouche JF; Couture F; Lemieux C
    Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):203-210. PubMed ID: 36646606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma.
    St-Pierre F; Gordon LI
    Future Oncol; 2023 Jan; 19(1):19-28. PubMed ID: 36651471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
    Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
    Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
    Topp MS; van Meerten T; Houot R; Minnema MC; Bouabdallah K; Lugtenburg PJ; Thieblemont C; Wermke M; Song KW; Avivi I; Kuruvilla J; Dührsen U; Zheng Y; Vardhanabhuti S; Dong J; Bot A; Rossi JM; Plaks V; Sherman M; Kim JJ; Kerber A; Kersten MJ
    Br J Haematol; 2021 Nov; 195(3):388-398. PubMed ID: 34590303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
    Neelapu SS; Locke FL; Bartlett NL; Lekakis LJ; Miklos DB; Jacobson CA; Braunschweig I; Oluwole OO; Siddiqi T; Lin Y; Timmerman JM; Stiff PJ; Friedberg JW; Flinn IW; Goy A; Hill BT; Smith MR; Deol A; Farooq U; McSweeney P; Munoz J; Avivi I; Castro JE; Westin JR; Chavez JC; Ghobadi A; Komanduri KV; Levy R; Jacobsen ED; Witzig TE; Reagan P; Bot A; Rossi J; Navale L; Jiang Y; Aycock J; Elias M; Chang D; Wiezorek J; Go WY
    N Engl J Med; 2017 Dec; 377(26):2531-2544. PubMed ID: 29226797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.